Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.